Announced Wed, 29 Apr · 17:43 IST

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+4.9%1-day move
₹29.10
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.9+10.0+15.5+21.3+15.3+4.1+0.7+0.0-0.7
Up moveDown movePending
AI summary

Shukra Pharmaceuticals Ltd has filed a disclosure with BSE confirming that it does not qualify as a 'Large Corporate' under SEBI regulations (circular dated October 19, 2023). The company states it does not meet the criteria specified in para 3.2 of the SEBI circular regarding fund-raising through debt securities. This is a routine compliance filing where the company is confirming its non-applicability under the regulatory framework for large entities. The filing was made on April 29, 2026, to the BSE Limited (Scrip Code: 524632).

Likely market impact

This filing has no direct impact on shareholders as it simply confirms the company is below the threshold to be classified as a Large Corporate. It indicates the company is smaller in scale and has fewer mandatory debt-related disclosure requirements compared to larger listed entities.